Management of patients with metastatic colorectal cancer: economic consequences of different treatment programs

Management of patients with metastatic colorectal cancer: economic consequences of different treatment programs

Authors

  • Stefania Lopatriello PBE Consulting, Verona 

  • Cristina Negrini PBE Consulting, Verona 

  • Domenico Amoroso Unità di Oncologia Medica, Ospedale Versilia Azienda USL n.12 di Viareggio e Istituto Toscano Tumori

  • Sara Donati Unità di Oncologia Medica, Ospedale Versilia Azienda USL n.12 di Viareggio e Istituto Toscano Tumori



DOI:

https://doi.org/10.7175/fe.v10i3.173

Keywords:

Oral, Infusional chemotherapy, Clinical pattern, Costs

Abstract

The clinical pattern of Metastatic ColoRectal Cancer patients, receiving first-line infusional 5-FU or oral capecitabine (CAP) chemotherapies, was valorized in the perspective of the Italian NHS. A cost-minimization analysis was implemented on the basis of retrospective data from 5 centers. 202 subjects: 126 receiving 5-FU-association, 10 5-FU-monotherapy; 31 CAP-association, 35 CAP-monotherapy. Therapeutic patterns differed as to chemotherapy administration resources consumption: 5-FU was administered in Day Hospital and CAP in the outpatient setting. Mean total cost/patient was in the range of € 6,841 (monotherapy-5-FU)- € 12,620 (association-5-FU) and € 2,056 (monotherapy-CAP)-€ 9,745 (association-CAP). The infusional administration route of 5-FU was the driver of costs.

Downloads

Published

2009-09-15

How to Cite

Lopatriello, S., Negrini, C., Amoroso, D., & Donati, S. (2009). Management of patients with metastatic colorectal cancer: economic consequences of different treatment programs. Farmeconomia. Health Economics and Therapeutic Pathways, 10(3), 129–134. https://doi.org/10.7175/fe.v10i3.173

Issue

Section

Review (Economic Analysis)

Similar Articles

<< < 4 5 6 7 8 9 10 11 12 13 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

Loading...